MedTrace Logo

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

NCT05599061 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-01-29

No results posted yet for this study

Summary

The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.

Conditions

Interventions

OTHER

FFR>0.80+ OCT with findings indicative of vulnerable plaque

Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI

OTHER

FFR>0.80+ OCT with findings indicative of vulnerable plaque

OPTIMAL MEDICAL TREATMENT (OMT)

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Fundación EPIC

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2028-12-01
Completion
2028-12-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05599061 on ClinicalTrials.gov